HER2 Positive Breast Cancer - pertuzumab + trastuzumab-pkrb - ER negative

Association details:

Biomarker:	ER negative
Cancer:	HER2 Positive Breast Cancer
Drug:	Perjeta (pertuzumab) (HER2 dimerization inhibitor) + Herzuma (trastuzumab-pkrb) (HER2 inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

NCRI 2020

Title:

Retrospective review of the efficacy and tolerability of neoadjuvant biosimilar Trastuzumab (Herzuma) in combination with Pertuzumab and chemotherapy in HER2-positive early breast cancer.

Published date:

11/03/2020

Excerpt:

61 patients received Pertuzumab+Herceptin/Herzuma as part of their NACT between January 2017 and June 2019….ypT0/ ypN0 was achieved in 48% of patients of H-group and 63% of Hz-group. ypT0/ypN0 was more likely if the tumours were grade 3 or ER-negative….When used in combination with Pertuzumab and chemotherapy, neoadjuvant biosimilar Herzuma is comparable to Herceptin in terms of efficacy and safety. The signal of superiority of Herzuma over Herceptin in achieving pCR during NACT...